Impacting our Commercial line of business only.
Blue Cross Blue Shield of North Dakota (BCBSND) is informing our provider community that the U.S. Food and Drug Administration (FDA) has approved multiple biosimilar products for the reference brand name medication, Stelara. Biosimilar products for Stelara are indicated to reduce signs and symptoms of various autoimmune disorders. These biosimilar agents are available in the market and offer additional safe and cost-effective options for management of autoimmune disorders.
Effective July 1, 2025, Selarsdi (ustekinumab-aekn), Steqeyma (ustekinumab-stba), and Yesintek (ustekinumab-kfce) will be the preferred biosimilar products on all BCBSND formularies. Stelara will be removed from formularies and will be a non-preferred medication. Current coverage for Stelara will remain the same through June 30, 2025.
Prior authorization (PA) approvals for Stelara will be terminated June 30, 2025, and new prior authorization approvals for Selarsdi (ustekinumab-aekn), Steqeyma (ustekinumab-stba), and Yesintek (ustekinumab-kfce) will be entered in its place effective July 1, 2025, through the original Stelara PA expiration date.
Utilization Management policies will be updated to reflect the formulary changes and will be available through bcbsnd.com on July 1, 2025.
Preferred Products Effective July 1, 2025
